M2 Pharma - Policy and Regulations

Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes

12 January 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Monday that the European Commission has approved Teizeild (teplizumab) to delay the onset of stag...

Futura Medical reports statistically significant female sexual function gains in WSD4000 study

12 January 2026 - Consumer healthcare group Futura Medical plc (AIM: FUM) reported on Monday positive results from an Early Feasibility Study of WSD4000, a topical treatment in development for female ...

GRIN Therapeutics doses first patient in global Phase 3 trial of investigational radiprodil for GRIN-NDD

12 January 2026 - GRIN Therapeutics Inc, a developer of precision therapeutics for neurodevelopmental disorders, announced on Friday that it has dosed the first patient in its global Phase 3 Beeline t...

Phanes Therapeutics reports clinical data on spevatamig chemotherapy combination in frontline treatment of mPDAC

12 January 2026 - Phanes Therapeutics Inc, a California-based clinical stage biotech company focused on innovative drug discovery and development in oncology, on Friday reported the first clinical dat...

Clover Biopharmaceuticals enrols first participants in Phase 2 trial of respiratory combination vaccine candidates

12 January 2026 - Clover Biopharmaceuticals Ltd (HKEX:02197), a China-based commercial-stage biotechnology company, announced on Monday that the first participants have been enrolled in a Phase 2 clin...

FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz

9 January 2026 - Swedish biopharmaceutical company Camurus (STO: CAMX), which develops long-acting medicines for severe and chronic diseases, said on Friday that the US Food and Drug Administration (F...